A 10-year follow-up study of the Norwegian ARCTIC trial published in Annals of the Rheumatic Diseases shows that an early treat-to-target strategy yields excellent long-term outcomes in early rheumatoid arthritis. Led by Dr. Lena Bugge Nordberg, the study reveals that 82% of participants were in clinical remission after a decade, with minimal joint damage progression. Achieving remission within two years strongly predicted decade-long disease suppression, while 15% of patients safely stopped all anti-rheumatic drugs.
Long-term clinical remission outcomes
- ▪Mean Disease Activity Score among ARCTIC trial participants dropped from 3.4 at baseline to 1.2 at year 2, and remained low at 1.1 at year 10.
- ▪In a 10-year follow-up of 179 surviving participants from the Norwegian ARCTIC trial, 82% met strict criteria for clinical remission following an initial treat-to-target strategy for early rheumatoid arthritis.
- ▪In the ARCTIC trial follow-up, disease remission was defined as a Disease Activity Score below 1.6, based on a 44-joint assessment, systemic inflammation markers, and patient evaluations.
Predictive value of early remission at ten years
- ▪Patients in the ARCTIC trial who did not reach clinical remission at year 2 exhibited significantly higher disease activity and lower physical function at year 10.
- ▪ARCTIC trial participants achieving sustained clinical remission at year 2 were significantly more likely to remain in remission at year 10 (89.9%) than poorer short-term responders (73.1%).
Joint damage and ultrasound findings at ten years
- ▪Approximately 80% of ARCTIC trial participants showed no joint Doppler signal of inflammation on ultrasound both at year 2 and at year 10.
- ▪In the 10-year ARCTIC trial follow-up published in Annals of the Rheumatic Diseases, participants showed a median change of 2.0 points in the modified van der Heijde-Sharp score for joint damage.
Medication usage trends over ten years
- ▪At the 10-year mark of the ARCTIC study, 44% of patients were taking a single conventional disease-modifying anti-rheumatic drug, almost always methotrexate, while 35% were using biologic agents.
- ▪Ten years after beginning treat-to-target therapy in the ARCTIC trial, 15% of patients had successfully discontinued all disease-modifying anti-rheumatic drugs.
Patient outlook and quality of life
- ▪A study led by Dr. Lena Bugge Nordberg concluded that treat-to-target strategy findings offer reassurance to newly diagnosed rheumatoid arthritis patients that remission, preserved function, and favorable survival are realistic long-term outcomes.
- ▪Participants in the 10-year ARCTIC trial follow-up demonstrated substantial improvements in physical function and health-related quality of life, approaching population norms.
Design and rationale of the ARCTIC trial
- ▪The ARCTIC trial randomized 230 early rheumatoid arthritis patients to two treat-to-target strategies, finding that adding joint ultrasound scans offered no significant advantage over conventional clinical remission targeting.
- ▪A treat-to-target strategy in rheumatoid arthritis involves titrating drug doses based on clinical remission benchmarks rather than sticking strictly to medication label dosages.
Trial enrollment and follow-up
- ▪Out of 230 original patients enrolled in the ARCTIC trial, 218 survived to 10 years, reflecting mortality rates comparable to general population statistics.
- ▪Among the 218 surviving patients invited for the 10-year ARCTIC trial follow-up, 39 were unable or unwilling to participate.
Story comments
Loading comments…